Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge
- 7 December 2009
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 125 (4) , 889-895.e7
- https://doi.org/10.1016/j.jaci.2009.09.012
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institutes of Health
This publication has 25 references indexed in Scilit:
- Basophil Histamine Release Decreases during Omalizumab Therapy in Allergic AsthmaticsInternational Archives of Allergy and Immunology, 2007
- Endocytosis, recycling, and degradation of unoccupied FcεRI in human basophilsJournal of Leukocyte Biology, 2007
- Accuracy of US Food and Drug Administration–cleared IgE antibody assays in the presence of anti-IgE (omalizumab)Journal of Allergy and Clinical Immunology, 2006
- Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challengeJournal of Allergy and Clinical Immunology, 2005
- Objective monitoring of nasal patency and nasal physiology in rhinitisJournal of Allergy and Clinical Immunology, 2005
- Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesisAnnals of Allergy, Asthma & Immunology, 2004
- Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils☆Journal of Allergy and Clinical Immunology, 2004
- Expression and modulation of FcϵRIα and FcϵRIβ in human blood basophilsJournal of Allergy and Clinical Immunology, 2001
- Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutionsJournal of Allergy and Clinical Immunology, 1992
- Inflammatory Mediators in Late Antigen-Induced RhinitisNew England Journal of Medicine, 1985